RTP Mobile Logo
New Biological Insights and Recent Therapeutic Advances in the Management of Lung Cancer
Released October 2015

Roundtable participants include Drs David P Carbone, Mark G Kris, Corey J Langer, Geoffrey R Oxnard, David R Spigel and Anne S Tsao. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    Lung cancer is increasingly being recognized as a heterogeneous group of tumors. Not long ago, it was clinically sufficient to make a differentiation between small cell lung cancer and non-small cell lung cancer (NSCLC). Individualized treatment decisions are increasingly driven by genetic biomarkers in addition to histological subtype and patient-specific characteristics. Determining which treatment approach is most appropriate in a given case requires careful consideration of patient characteristics, biomarkers and available health system resources. Oncology clinicians must possess a clear understanding of the benefits and risks of each of the various available options and how best to integrate emerging data and agents into the treatment algorithm. This CME program uses a roundtable discussion with leading clinical investigators to provide biological insights into the recent therapeutic advances in the management of lung cancer. By reviewing the available clinical trial data and relevant case scenarios, this initiative will help illustrate gaps in medical knowledge and illuminate treatment ambiguities pertinent to this disease.

    LEARNING OBJECTIVES

    • Develop an evidence-based strategy for the treatment of localized NSCLC, exploring options for adjuvant systemic therapy.
    • Devise an evidence-based approach to the selection of induction and maintenance biologic therapy and/or chemotherapy for patients with advanced pan-wild-type NSCLC.
    • Employ an understanding of personalized medicine to individualize the use of available EGFR inhibitors in the treatment of NSCLC before and after disease progression on an EGFR tyrosine kinase inhibitor (TKI).
    • Communicate the efficacy and safety of crizotinib, ceritinib and emerging ALK inhibitors to appropriate patients with NSCLC, considering the predictive utility of ALK and ROS1 mutation testing.
    • Evaluate the emerging data from clinical trials of the third-generation EGFR TKIs rociletinib and AZD9291 in EGFR mutation-positive NSCLC.
    • Describe emerging data on the efficacy and safety of tumor immunotherapy directed at the PD-1/PD-L1 pathway in lung cancer, and consider this information when counseling patients regarding current treatment options and clinical trial participation.
    • Recognize the results of recently completed Phase III trials examining the efficacy and safety of the novel monoclonal antibodies necitumumab and ramucirumab for patients with advanced NSCLC.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity contains an audio component.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDr Spigel has no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr CarboneConsulting Agreements: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Eisai Inc, Genentech BioOncology, GlaxoSmithKline, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc. Dr KrisAdvisory Committee: Daiichi Sankyo Inc; Consulting Agreements: Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology; Contracted Research: Pfizer Inc, Puma Biotechnology Inc; Other Remunerated Activities: Roche Laboratories Inc. Dr LangerAdvisory Committee: Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clarient Inc, Clovis Oncology, Genentech BioOncology, Lilly, Merck, Myriad Genetic Laboratories Inc, Roche Laboratories Inc; Consulting Agreements: Abbott Laboratories, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly, Merck, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Genentech BioOncology, GlaxoSmithKline, Lilly, Merck, Pfizer Inc, Takeda Oncology, Veridex LLC; Data Safety Monitoring Committee: Amgen Inc, Synta Pharmaceuticals Corp. Dr OxnardAdvisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Genentech BioOncology, Sanofi; Consulting Agreement: AstraZeneca Pharmaceuticals LP; Contracted Research: Pfizer Inc. Dr TsaoAdvisory Committee: Astellas Scientific and Medical Affairs Inc, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Lilly, MedImmune Inc, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, MedImmune Inc, Merck.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Biodesix Inc, Clovis Oncology, Foundation Medicine, Genentech BioOncology, Lilly, Merck and Novartis Pharmaceuticals Corporation.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: October 2015
    Expiration date: October 2016

Acknowledge and close

Listen to audio:
New Biological Insights and Recent Therapeutic Advances in the Management of Lung Cancer
Released October 2015

Roundtable participants include Drs David P Carbone, Mark G Kris, Corey J Langer, Geoffrey R Oxnard, David R Spigel and Anne S Tsao. (Audio Content)

Read print: